ZEVRA THERAPEUTICS INC. - COMMON STOCK

8,0000

02-мая-25 16:45:00

15 мин. задержка

Акции

+0,3600

+4,71%

Сегодняшний диапазон

7,6600 - 8,1000

ISIN

N/A

Источник

NASDAQ

Zevra Therapeutics to Participate in the Citizens Life Science Conference

01 май 2025 16:05:00 Источник Nasdaq GlobeNewswire
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

21 апр 2025 07:22:15 Источник Nasdaq GlobeNewswire
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

17 апр 2025 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

07 апр 2025 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Files Preliminary Proxy

31 мар 2025 16:12:17 Источник Nasdaq GlobeNewswire
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

11 мар 2025 16:05:15 Источник Nasdaq GlobeNewswire
Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

28 фев 2025 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

27 фев 2025 07:30:59 Источник Nasdaq GlobeNewswire
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

26 фев 2025 09:46:16 Источник Nasdaq GlobeNewswire
Zevra to Participate at Upcoming Investor Conferences

24 фев 2025 16:02:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

30 янв 2025 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Conferences

29 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

17 дек 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces Organizational Changes

06 дек 2024 17:00:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Conferences

26 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

21 ноя 2024 16:51:59 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

12 ноя 2024 16:05:01 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

11 ноя 2024 16:36:41 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

06 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

31 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.